# CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab

> **NCT02634970** · PHASE4 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Wet Age-related Macular Degeneration (Wet AMD)

## Interventions

- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT02634970
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-03
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02634970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02634970, "CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02634970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*